1xbetÍøÒ³°æ

ͼ1. HIV-1·¢ÉúÌÓÒݵĽṹ»ù´¡

ͼ2. 3BNC117ºÍVRC01ÁÙ´²ÖÎÁÆÇ°ºó¶ÔӦλµã°±»ùËáµÄ±ä»¯

°¬×̲¡£¨AIDS£©ÊÇÍþвÈËÀཡ¿µµÄÖØ´ó´«È¾ÐÔ¼²²¡Ö®Ò»¡£×Ô1981Äê·¢ÏÖÒÔÀ´£¬ÒÑÔÚÈ«ÇòѸËÙÂûÑÓ¡£½ØÖÁ2018Äêµ×£¬Ô¼ÓÐ7730ÍòÈ˸ÐȾ£¬ÆäÖÐÔ¼3540ÍòÈËÒÑËÀÓÚ°¬×ÌÏà¹ØÐÔ¼²²¡¡£¾¡¹ÜÊÀ½ç¸÷µØͶÈë´óÁ¿µÄÈËÁ¦ºÍÎïÁ¦£¬µ«ÖÁ½ñÈÔÎÞÓÐЧµÄÒßÃçºÍ¸ùÖεÄÊֶΡ£°¬×̲¡²¡¶¾£¨Human Immunodeficiency virus HIV£©ÊÇ°¬×̲¡µÄÔªÐס£Ö÷Òª¸ÐȾºÍɱÉËCD4+TÁÜ°Íϸ°û£¬ÆÆ»µÈËÌåÃâÒßϵͳ£¬ÓÕ·¢Ò»ÏµÁлú»áÐÔ¸ÐȾºÍÖ×Áö£¬×îÖÕµ¼ÖÂËÀÍö¡£ÓëÆäËû²¡¶¾Ïà±È£¬°¬×̲¡²¡¶¾¾ßÓи´ÖÆ¿ì¡¢¸ßÍ»±äµÈÌصã¡£½ü¼¸Äê´Ó¡°¾«Ó¢¸ÐȾÕß¡±ÌåÄÚ·ÖÀë³öÀ´µÄһϵÁйãÆ×ÖкͿ¹Ì壬չʾ³öÁËÇ°ËùδÓеĿ¹²¡¶¾»îÐԺ͹ãÆ×ÐÔ£¬¶ÔÈ«ÊÀ½çÁ÷ÐеÄ90%ÒÔÉϵݬ×̲¡²¡¶¾¾ßÓг¬Ç¿µÄÖкÍ×÷Óã¬Îª°¬×ÌÖÎÁƺÍÔ¤·ÀÌṩÁËÓÐÁ¦µÄÎäÆ÷£¬Ò²Îª°¬×̲¡ÒßÃçÉè¼ÆÌṩÁ˾«×¼µÄ°Ð±ê¡£ÕâЩ¹ãÆ×ÖкͿ¹ÌåÖ÷Ҫʶ±ð°¬×̲¡²¡¶¾Ä¤µ°°×ÉϵÄÁù¸ö±íλ£º£¨1£©CD4½áºÏλµã£¨CD4bs£©£»£¨2£©V1/V2 »· £¨V1/V2 loop£©£»£¨3£© glycan-V3 »· (glycan-V3 loop)£»£¨4£©ÈÚºÏëÄ (fusion peptide)£»£¨5£©ÑÇ»ù½çÃæ £¨subunit interface£©£»£¨6£©gp41µÄ½üĤ¶ËÇøÓò(MPER)¡£ÆäÖÐÒÔʶ±ðCD4½áºÏλµãµÄ¹ãÆ×ÖкͿ¹Ì壨ÈçVRC01¡¢3BNC117¡¢N6µÈ£©ÊýÁ¿×î¶à£¬»úÖÆÑо¿×îÉî¿Ì£¬Ö÷Ҫͨ¹ý×èÖ¹²¡¶¾ÓëCD4ÊÜÌå½áºÏºÍFc½éµ¼µÄϸ°ûɱÉË·¢»ÓÖкÍ×÷ÓᣴËÍ⣬¶à¸öʶ±ðCD4½áºÏλµãµÄ¹ãÆ×ÖкͿ¹ÌåÒѾ­ÔÚÁÙ´²ÊÔÑéÖÐչʾÁËÁîÈ˹ÄÎèµÄЧ¹û¡£µ«ÊÇ£¬¹ãÆ׿¹ÐÔ°¬×̲¡²¡¶¾µÄ·¢ÏÖ£¬½Òʾ²¡¶¾ÔÚ×ÔȻ״̬Ï£¬Äܹ»²»¶Ï¸ß¶È±äÒì¶øÇÉÃîÌÓÒݹãÆ×ÖкͿ¹ÌåµÄʶ±ð£¬ÕæʵÌåÏÖÁË¡°µÀ¸ßÒ»³ß£¬Ä§¸ßÒ»ÕÉ¡±µÄ²¡¶¾ÓëÃâÒßϵͳ֮¼ä¸´ÔÓ½ÏÁ¿¹Øϵ£¬Îª¹ãÆ×ÖкͿ¹ÌåµÄÁÙ´²Ê¹ÓÃÌá³öÁËÇ°ËùδÓеÄÌôÕ½¡£

´ËÑо¿ÓÉ1xbetÍøÒ³°æÕÅÁÖçù½ÌÊÚÍŶÓ¡¢ÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿ÔºÒßÃçÑо¿ÖÐÐÄÖÜͬÇìÑо¿Ô±ºÍÖйúÒ½¿Æ´óѧÉкì½ÌÊÚÍŶӺÏ×÷Íê³É¡£1xbetÍøÒ³°æ²©Ê¿ÉúÖÜÅÎÅÎΪµÚÒ»×÷Õߣ¬ÕÅÁÖçù½ÌÊÚºÍÖÜͬÇìÑо¿Ô±Îª¹²Í¬Í¨Ñ¶×÷Õß¡£¸ÃÑо¿Óɹú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢¹ú¼Ò¿Æ¼¼ÖØ´óרÏî¡¢±±¾©ÊпÆѧ¼¼ÊõίԱ»á¡¢¸Ç´Ä»ù½ðÖйú´óÌôÕ½ÏîÄ¿µÈ×ÊÖúÍê³É¡£

¡òÎÄÕÂÁ´½Ó£ºhttps://doi.org/10.1371/journal.ppat.1007819